Boston Scientific Corporation (BSX) , despite industrywide macroeconomic upheavals,  has been seeing strong growth momentum across its target markets. Earlier this month, the company posted robust fourth-quarter 2024 results, surpassing market expectations and setting a positive outlook for 2025. These have led to upward revisions in analyst estimates.The Zacks Consensus Estimate for first-quarter 2025 earnings per share has been revised upward by 3 cents over the past 60 days, with six analysts upgrading t ...

Financial Performance - In 2024, Boston Scientific's net sales reached $16.747 billion, a 17.6% increase from $14.240 billion in 2023, driven by operational net sales growth of 18.5%[184] - The reported net income attributable to common stockholders in 2024 was $1.853 billion, or $1.25 per diluted share, compared to $1.570 billion, or $1.07 per diluted share in 2023[184] - Total net sales increased to $16.747 billion in 2024 from $14.240 billion in 2023, representing a growth of 17.6%, with operational growth of 13.1% and an 80 basis point negative impact from foreign currency fluctuations[202][203] Business Segments - The Endoscopy business generated net sales of $2.687 billion in 2024, representing 16% of consolidated net sales, with an 8.3% increase from 2023[189] - Urology products net sales were $2.200 billion in 2024, accounting for 13% of consolidated net sales, reflecting a 12.0% increase compared to 2023[191] - Neuromodulation products net sales reached $1.106 billion in 2024, a 13.3% increase from 2023, representing 7% of consolidated net sales[193] - Cardiology products net sales were $8.344 billion in 2024, a 24.4% increase from 2023, making up 50% of consolidated net sales[195] - Peripheral Interventions net sales totaled $2.410 billion in 2024, a 14.2% increase from 2023, representing 14% of consolidated net sales[197] Growth and Acquisitions - The company experienced organic net sales growth of 16.4% in 2024, with acquisitions contributing an additional 210 basis points[184] - The acquisition of Axonics in Q4 2024 positively impacted Urology's organic net sales growth by 330 basis points[191] - Boston Scientific aims to expand its global presence, particularly in Emerging Markets, to drive net sales and market share growth[199] - Emerging Markets net sales accounted for 16% of consolidated net sales in both 2024 and 2023, with a growth of 16.1% in 2024 driven by operational growth of 19.6% despite a 360 basis point negative impact from foreign currency fluctuations[200] Expenses and Profitability - Gross profit for 2024 was $11.490 billion, with a gross profit margin of 68.6%, down from 69.5% in 2023, primarily due to inventory charges and strategic manufacturing capacity investments[204][205] - Selling, General and Administrative (SG&A) expenses rose to $5.984 billion in 2024, a 15% increase from 2023, while as a percentage of net sales, it decreased by 70 basis points[209] - Research and Development (R&D) expenses increased to $1.615 billion in 2024, a 14% rise compared to 2023, reflecting the company's commitment to advancing medical technologies[211] Debt and Financing - Total debt as of December 31, 2024, was $10.746 billion, an increase from $9.102 billion in 2023, with current debt obligations rising to $1.778 billion[242] - Cash used for investing activities in 2024 was $(5.687) billion, primarily for acquisitions including Axonics and Silk Road Medical[235] - Cash provided by financing activities included $2.145 billion from the Eurobonds offering, used to fund the Axonics acquisition and repay senior notes[236] Tax and Compliance - The reported tax rate for 2024 was 19.1%, down from 19.8% in 2023, with a rate from continuing operations of 18.0%[222] - The company expects the impact of the Pillar Two global minimum tax on its 2024 tax rate to be immaterial, with similar expectations for 2025[226] - The company expects to incur significant expenditures related to compliance with the EU MDR regulatory requirements, which are not considered ordinary course expenditures[285] Restructuring and Future Plans - The company recorded restructuring charges of $16 million and restructuring-related charges of $212 million in 2024 as part of its global restructuring program[217] - The 2023 Restructuring Plan is estimated to incur total pre-tax charges of approximately $450 million to $550 million, with cash outlays expected to be between $350 million and $450 million[251] - The restructuring plan aims to reduce gross annual pre-tax expenses by approximately $225 million to $275 million as benefits are realized[251] Legal and Regulatory Matters - The company is involved in various legal and regulatory proceedings, which may require significant expenditures or impact product sales[272] - Anticipated costs of settlement and damages for product liability claims are accrued based on historical experience, with significant judgment required in estimating these accruals[272] Internal Controls and Risk Management - The company's internal control over financial reporting was assessed as effective as of December 31, 2024[289] - The independent auditor expressed an unqualified opinion on the effectiveness of the company's internal control over financial reporting[294] - The company uses a risk management program that includes derivative financial instruments to address market risks from changes in currency exchange rates and interest rates[303]

Boston Scientific (BSX) is gaining from new product launches and accretive acquisitions. Yet, unfavorable currency movement and macroeconomic concerns are major dampeners. The stock carries a Zacks Rank #3 (Hold).Factors Driving BSX SharesBoston Scientific’s Endoscopy business within MedSurg is witnessing strong growth in endoluminal surgery and single-use imaging franchises, along with sustained growth of the AXIOS platform, where the company is reinvesting to drive expanded indications. It recently receiv ...

POLAND - 2024/11/21: In this photo illustration, the Boston Scientific company logo is seen ... [+] displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesBoston Scientific stock (NYSE: BSX) has gained 3% in the five days since its Q4 earnings report last week. Although the company exceeded expectations with both its results and guidance, the modest stock increase may be due to the significant price appreciation ah ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, February 10th:Boston Scientific Corporation (BSX) : This medical devices company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Boston Scientific’s shares gained 19.3% over the last three months compared with the S&P 500’s advance of 0.4%. The company possesses a Momentum Score  of A.Enova International, Inc. (ENVA) : Thi ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Peoples Financial Services Corp. (PFIS) : This bank holding company for Peoples Security Bank and Trust Company has seen the Zacks Consensus Estimate for its current year earnings increasing 10.2% over the last 60 days.Boston Scientific Corporation (BSX) : This medical devices company has seen the Zacks Consensus Estimate for its current year earnings increasing 5.2% over the last 60 days.Enova International, Inc. (ENVA) : This technolo ...

2025年2月5日， 波士顿科学 公布了2024年第四季度及全年业绩。 其中， 电生理业务 第四季度销售额为 6.49亿美元 ，全年销售额为 19亿美元 ，分别同比增 长近 171% 和 138% 。 财报称，在2024年初获得 FDA 批准后，其 FARAPULSE脉冲场消融系统 到2024年底的销售额 超过10亿美元（72.88亿美元） 。 该公司领导层此前曾将 FARAPULSE描述为 波士顿科学公司历史上最具变革性的产品 。自商业推出以来，它推动了电生理学销售额的增长，包括 2024 年第 一季度的同比增长 70%、第二季度的 125% 和第三季度的 177%。 波士顿科学董事长兼CEO Mike Mahoney 说，"2024年是波科历史上表现最佳的年份之一，得益于我们的创新产品组合、FARAPULSE系统的上市，以及跨业 务和地区的临床与商业化突破。我们已奠定强劲增长基础，并将持续变革全球数百万患者的生活。" # 何为FARAPULSE 系统？ 作为 全球被研究和使用最多的PFA （脉冲电场消融） 系统 ，波士顿科学的FARAPULSE 系统迄今已治疗超过7万名患者。 FARAPULSE 系统可通 ...

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In the 'long' context, investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving that way. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.While many investors like to look for moment ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Is Boston Scientific (BSX) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Boston Scientific is one of 1012 individual stocks in the Medical sector. Collectively, these companies sit at #3 in the Zacks Sector Rank. The Zacks Sector Rank includes 16 different groups and is ...

2025年2月5日， 波士顿科学 公布了 2024年第四季度及全年业绩 ， 第四季度销售额 45.61亿美元（约合332亿人民币） ，同比增长22.4%；全年总营收 167.47亿美元（约合1220亿人民币） ， 同比 增长17.6%。 # 财报亮点 第四季度的净销售额 为45.61亿美元 ，同比增长22.4%（报告）、23.1%（运营）和19.5%（有机）；每股收益（EPS）为0.38美元，同比增长11.8%，调整后 为0.70美元，同比增长27.3%； 毛利率为67.9%，同比下降130个基点；调整后为70.6%，同比增长20个基点；营业利润率为14.8%，同比下降90个基点；调整 后为27.4%，同比增长80个基点。 全年净销售额为167.47亿美元 ，同比增长17.6%（报告）、18.5%（运营）和16.4%（有机）；每股收益（EPS）为1.25美元，同比增长20.0%，调整后为2.51 美元，同比增长100.0%；毛利率为68.6%，同比下降90个基点；调整后为70.3%，同比下降40个基点；营业利润率为15.5%，同比下降100个基点，调整后为 27.0%，同比增长70个基点。 | Q4 & FY ...